© 2026 CellCarta - All rights reserved.
Download the Case Study
What If Your Biomarker Assay Could Be Trial-Ready Months Sooner?
Get the full responder vs non-responder dataset and methodology.
Get the full responder vs non-responder dataset and methodology.
Download the Case Study
One tissue section.
Clear phenotypic differences.
Advancing Oncology Biomarker Strategies During ASCO 2026
In a 20-plex hyperplex analysis of tissue samples from patients with muscle-invasive bladder cancer treated with neo-adjuvant immunotherapy, CellCarta's clinical-grade COMET workflow highlighted distinct differences in immune composition, spatial proximity, and tissue organization between an immunotherapy responder and a non-responder, all from a single slide per patient.
WHAT SEPARATES A RESPONDER FROM A NON-RESPONDER?
One tissue section.Clear phenotypic differences.
WHAT SEPARATES A RESPONDER FROM A NON-RESPONDER?
From early-stage biotechs to established biopharma, understanding why some patients respond better than others is essential.
up to 40
20-plex
0.94–0.96
markers on a single slide
hyperplex spatial analysis
cross-site concordance (ICC)
✔ Clinical-grade workflows
✔ Regulatory-ready data
✔ Cross-site validated (US + EU)
✔ Global CRO, owned harmonized labs
THE PLATFORM
Built on the COMET.
How the COMET works: an integrated staining and scanning system analyzing up to 40 markers on a single slide through iterative stain-image-elute cycles, built for the standardized, documented protocols clinical trial contexts demand.
The assay was developed and validated for accuracy, sensitivity, specificity, and cross-site concordance between CellCarta's labs in Lake Forest, California and Antwerp, Belgium.
THE CHALLENGE
Hyperplex data eliminates inter-slide variability, but introduces it's own challenges.
By reading dozens of markers from a single slide, spatial biology approaches minimize tissue use and remove slide-to-slide variability. But it comes with its own challenges: huge data volumes, and the requirement for stringent phenotyping consistency and analytical rigor to make accurate, actionable conclusions.
INSIDE THE CASE STUDY
The complete responder vs non-responder dataset.
01
Phenotype composition how immune, stromal, and tumor proportions differed between the two cases
02
Spatial distance, co-localization and niche analysis
03
04
How we build global assays for comparable results, regardless of data collection location
05
What it means for IO programs how tissue organization, not just cell counts, reflects response
See what a clinical-grade hyperplex workflow can reveal.
Download the full case study, or connect with our team to discuss your program's needs.
The clinical-grade, platform agnostic workflow that turns hyperplex image data into reliable, interpretable biological findings
up to 40
markers on a single slide
20-plex
0.94–0.96
hyperplex spatial analysis
cross-site concordance (ICC)
In a 20-plex hyperplex analysis of tissue samples from patients with muscle-invasive bladder cancer treated with neo-adjuvant immunotherapy, CellCarta's clinical-grade COMET workflow highlighted distinct differences in immune composition, spatial proximity, and tissue organization between an immunotherapy responder and a non-responder, all from a single slide per patient.
From early-stage biotechs to established biopharma, understanding why some patients respond better than others is essential.
✔ Clinical-grade workflows
✔ Regulatory-ready data
✔ Cross-site validated (California + Belgium)
✔ Global CRO, owned harmonized labs
Hyperplex data eliminates inter-slide variability, but introduces it's own challenges.
THE CHALLENGE
By reading dozens of markers from a single slide, spatial biology approaches minimize tissue use and remove slide-to-slide variability. But it comes with its own challenges: huge data volumes, and the requirement for stringent phenotyping consistency and analytical rigor to make accurate, actionable conclusions.
THE PLATFORM
Built on the COMET.
How the COMET works: an integrated staining and scanning system analyzing up to 40 markers on a single slide through iterative stain-image-elute cycles, built for the standardized, documented protocols clinical trial contexts demand.
The assay was developed and validated for accuracy, sensitivity, specificity, and cross-site concordance between CellCarta's labs in Lake Forest, California and Antwerp, Belgium.
01
INSIDE THE CASE STUDY
The complete responder vs non-responder dataset.
Phenotype composition how immune, stromal, and tumor proportions differed between the two cases
02
03
05
04
Spatial distance, co-localization and niche analysis
What it means for IO programs how tissue organization, not just cell counts, reflects response
How we build global assays for comparable results, regardless of data collection location
The clinical-grade, platform agnostic workflow that turns hyperplex image data into reliable, interpretable biological findings
See what a clinical-grade hyperplex workflow can reveal.
Download the full case study, or connect with our team to discuss your program's needs.
PBMC Processing
Same-day PBMC processing following robust SOPs across labs in NA, EU, Australia, and China.
PBMC Processing
Same-day PBMC processing following robust SOPs across labs in NA, EU, Australia, and China.
What Our Clients Say
The Lake Forest Expertise
“CellCarta was able to present a proposal in less than a week and they were ready to contract to get kits to our sites as soon as possible. They offered expedited start up without breaking the bank on costs to get the database and lab manual ready for review and sign off faster than any other central lab I've come across.”
Lead Outsourcing Director, Biopharma
The Lake Forest Expertise
“CellCarta was extremely helpful with the data analysis: great shout out to the data analysis team! The team in MTL was super fast and super professional!”
Biopharma Partner
The Lake Forest Expertise
"CellCarta’s project managers are supportive and attentive — they coordinate with your data team, CRO/CRAs, and other vendors as needed. They don't wait for us as the sponsor to bring issues up; they bring concerns to our attention and come prepared with resolution options.”
Lead Outsourcing Director, Biopharma
What Our Clients Say
“CellCarta was able to present a proposal in less than a week and they were ready to contract to get kits to our sites as soon as possible. They offered expedited start up without breaking the bank on costs to get the database and lab manual ready for review and sign off faster than any other central lab I've come across.”
Lead Outsourcing Director, Biopharma
“CellCarta was extremely helpful with the data analysis: great shout out to the data analysis team! The team in MTL was super fast and super professional!”
Biopharma Partner
"CellCarta’s project managers are supportive and attentive — they coordinate with your data team, CRO/CRAs, and other vendors as needed. They don't wait for us as the sponsor to bring issues up; they bring concerns to our attention and come prepared with resolution options.”
Lead Outsourcing Director, Biopharma